CVALF
Price
$1.19
Change
-$0.05 (-4.03%)
Updated
Dec 26 closing price
Capitalization
34.66M
Intraday BUY SELL Signals
SMMT
Price
$18.14
Change
-$0.24 (-1.31%)
Updated
Dec 26 closing price
Capitalization
13.5B
74 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CVALF vs SMMT

Header iconCVALF vs SMMT Comparison
Open Charts CVALF vs SMMTBanner chart's image
Covalon Technologies
Price$1.19
Change-$0.05 (-4.03%)
Volume$5.25K
Capitalization34.66M
Summit Therapeutics
Price$18.14
Change-$0.24 (-1.31%)
Volume$1.2M
Capitalization13.5B
CVALF vs SMMT Comparison Chart in %
CVALF
Daily Signal:
Gain/Loss:
SMMT
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CVALF vs. SMMT commentary
Dec 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVALF is a Hold and SMMT is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 28, 2025
Stock price -- (CVALF: $1.19 vs. SMMT: $18.14)
Brand notoriety: CVALF and SMMT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CVALF: 48% vs. SMMT: 46%
Market capitalization -- CVALF: $34.66M vs. SMMT: $13.5B
CVALF [@Biotechnology] is valued at $34.66M. SMMT’s [@Biotechnology] market capitalization is $13.5B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CVALF’s FA Score shows that 0 FA rating(s) are green whileSMMT’s FA Score has 1 green FA rating(s).

  • CVALF’s FA Score: 0 green, 5 red.
  • SMMT’s FA Score: 1 green, 4 red.
According to our system of comparison, SMMT is a better buy in the long-term than CVALF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CVALF’s TA Score shows that 4 TA indicator(s) are bullish while SMMT’s TA Score has 4 bullish TA indicator(s).

  • CVALF’s TA Score: 4 bullish, 4 bearish.
  • SMMT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both CVALF and SMMT are a good buy in the short-term.

Price Growth

CVALF (@Biotechnology) experienced а -4.80% price change this week, while SMMT (@Biotechnology) price change was +1.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.36%. For the same industry, the average monthly price growth was +0.27%, and the average quarterly price growth was +54.56%.

Reported Earning Dates

SMMT is expected to report earnings on Mar 12, 2026.

Industries' Descriptions

@Biotechnology (+0.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SMMT($13.5B) has a higher market cap than CVALF($34.7M). SMMT has higher P/E ratio than CVALF: SMMT (26.36) vs CVALF (23.27). SMMT YTD gains are higher at: 1.653 vs. CVALF (-46.875). CVALF has higher annual earnings (EBITDA): 3.14M vs. SMMT (-921.45M). SMMT has more cash in the bank: 239M vs. CVALF (18.1M). CVALF has less debt than SMMT: CVALF (1.28M) vs SMMT (5.43M). CVALF has higher revenues than SMMT: CVALF (33M) vs SMMT (0).
CVALFSMMTCVALF / SMMT
Capitalization34.7M13.5B0%
EBITDA3.14M-921.45M-0%
Gain YTD-46.8751.653-2,836%
P/E Ratio23.2726.3688%
Revenue33M0-
Total Cash18.1M239M8%
Total Debt1.28M5.43M24%
FUNDAMENTALS RATINGS
CVALF vs SMMT: Fundamental Ratings
CVALF
SMMT
OUTLOOK RATING
1..100
5024
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
94
Overvalued
PROFIT vs RISK RATING
1..100
8658
SMR RATING
1..100
75100
PRICE GROWTH RATING
1..100
8662
P/E GROWTH RATING
1..100
788
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CVALF's Valuation (72) in the null industry is in the same range as SMMT (94) in the Biotechnology industry. This means that CVALF’s stock grew similarly to SMMT’s over the last 12 months.

SMMT's Profit vs Risk Rating (58) in the Biotechnology industry is in the same range as CVALF (86) in the null industry. This means that SMMT’s stock grew similarly to CVALF’s over the last 12 months.

CVALF's SMR Rating (75) in the null industry is in the same range as SMMT (100) in the Biotechnology industry. This means that CVALF’s stock grew similarly to SMMT’s over the last 12 months.

SMMT's Price Growth Rating (62) in the Biotechnology industry is in the same range as CVALF (86) in the null industry. This means that SMMT’s stock grew similarly to CVALF’s over the last 12 months.

SMMT's P/E Growth Rating (8) in the Biotechnology industry is significantly better than the same rating for CVALF (78) in the null industry. This means that SMMT’s stock grew significantly faster than CVALF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CVALFSMMT
RSI
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
59%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
70%
Bullish Trend 3 days ago
88%
MACD
ODDS (%)
Bearish Trend 3 days ago
72%
Bullish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
66%
Bullish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
65%
Bullish Trend 3 days ago
89%
Advances
ODDS (%)
Bullish Trend 19 days ago
62%
Bullish Trend 7 days ago
85%
Declines
ODDS (%)
Bearish Trend 10 days ago
70%
Bearish Trend 12 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
62%
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
CVALF
Daily Signal:
Gain/Loss:
SMMT
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MMT4.680.02
+0.43%
MFS Multimarket Income Trust
IBTQ25.540.02
+0.06%
iShares iBonds Dec 2035 Term Trsy ETF
CLOI53.02-0.01
-0.02%
VanEck CLO ETF
INQQ15.06-0.21
-1.39%
INQQ The India Internet ETF
OWNB22.65-0.38
-1.63%
Bitwise Bitcoin Standard Corporations ETF

CVALF and

Correlation & Price change

A.I.dvisor tells us that CVALF and SMMT have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CVALF and SMMT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CVALF
1D Price
Change %
CVALF100%
-4.03%
SMMT - CVALF
27%
Poorly correlated
-1.31%
AKBLF - CVALF
21%
Poorly correlated
N/A
TARA - CVALF
21%
Poorly correlated
+1.09%
MBIO - CVALF
20%
Poorly correlated
-2.86%
BVNKF - CVALF
11%
Poorly correlated
N/A
More

SMMT and

Correlation & Price change

A.I.dvisor indicates that over the last year, SMMT has been closely correlated with BCDA. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if SMMT jumps, then BCDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SMMT
1D Price
Change %
SMMT100%
-1.31%
BCDA - SMMT
70%
Closely correlated
N/A
BNTX - SMMT
52%
Loosely correlated
-0.54%
TIL - SMMT
52%
Loosely correlated
-1.31%
IDYA - SMMT
42%
Loosely correlated
-1.35%
VBIZF - SMMT
42%
Loosely correlated
N/A
More